User: Guest  Login
Less Searchfields
Simple search
Title:

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

Document type:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Article
Author(s):
Graux, Carlos; Sonet, Anne; Maertens, Johan; Duyster, Justus; Greiner, Jochen; Chalandon, Yves; Martinelli, Giovanni; Hess, Dagmar; Heim, Dominik; Giles, Francis J; Kelly, Kevin R; Gianella-Borradori, Athos; Longerey, Blandine; Asatiani, Ekaterine; Rejeb, Narmyn; Ottmann, Oliver G
Abstract:
A phase I dose-escalation study of MSC1992371A, an oral aurora kinase inhibitor, was carried out in patients with hematologic malignancies. Patients received escalating doses either on days 1-3 and 8-10 (n=36) or on days 1-6 (n=39) of a 21-day cycle. The maximum tolerated doses were 37 and 28 mg/m(2)/day, respectively. Dose-limiting toxicities included severe neutropenia with infection and sepsis, mucositis/stomatitis, and diarrhea. Complete responses occurred in 3 patients. Four disease-specifi...     »
Journal title abbreviation:
Leuk Res
Year:
2013
Journal volume:
37
Journal issue:
9
Pages contribution:
1100-6
Language:
eng
Fulltext / DOI:
doi:10.1016/j.leukres.2013.04.025
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/23746966
Print-ISSN:
0145-2126
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX